Melatonin for Treatment of Delirium in Critically Ill Adult Patients
Key facts
- Who runs it
- Ciusss de L'Est de l'Île de Montréal
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 1 Feb 2023
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Melatonin
- Placebo
- Record updated
- 23 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Patients aged 18 years or older admitted to the intensive care unit
- Anticipated ICU stay > 48 hours
- ICDSC score greater than or equal to 4 for a maximum of 48 hours prior to randomization
Who cannot take part
- Use of melatonin within 24 hours prior to randomization
- Diagnosis of delirium prior to ICU admission
- Absolute contraindication to receive enteral medication
- Known allergy or hypersensitivity to melatonin or to ingredients in ORA-BLEND SF®
- Presence of severe structural brain injury (intracranial hemorrhage or traumatic brain injury), severe major neurocognitive disorder, advanced neurodegenerative disease or hepatic encephalopathy
- Diagnosis of schizophrenia, bipolar affective disorder, psychotic depression, uremic encephalopathy or alcohol withdrawal
- Presence of active seizures, coma, aphasia or severe intellectual disability
- Limited short-term vital prognosis
- Pregnancy or breastfeeding
- Inability to understand or speak English or French
- Total blindness
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Delirium
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients. From a feasibility perspective, the investigators believe that the proposed design will achieve the minimum enrollment rate necessary to conduct a future RCT on a larger scale.
The 2 groups in the trial
- Enteral melatonin 9 mgTreatment being tested
Melatonin 9 mg from a 1 mg/mL oral suspension of melatonin in ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.
Treatment: Melatonin
- Enteral placeboPlacebo, for comparison
ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.
Treatment: Placebo
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- DELIRE-ICU: A Randomised Controlled Feasibility Trial of Melatonin vs Placebo in the Treatment of Delirium in the Intensive Care Unit
- Criteria questions
- Built from NCT05713877, who can take part
- Record updated
- 23 March 2026